This Redcap database - a list of all patients who have indicated interest in being contacted for participation in Stanford Diabetes Research (T1D + T2D). https://redcap.link/t1dt2dresearch.

Information
Age:2– 70 years
Main Eligibility Criteria:
-T1D and T2D
-Any device or mode of insulin delivery
-Currently English only
Duration Time for Pt in Study: Any amount
Cross Recruitment OK?: Yes
Contact:
PI: Darrell Wilson, MD
Lead CRC: Sarah Hanes sjhanes@stanford.edu

Phase 1 Screening: testing for presence of diabetes related autoantibodies. Phase 2 Monitoring: Annual retesting if one autoantibody is positive; Semi-annual study visits if 2 or more autoantibodies are positive. Potential entry into T1D prevention studies.

Information
Age:2.5 – 45 years
Main Eligibility Criteria:
-Relatives of patients with T1D
-English and Spanish Speakers
-Please discuss subjects with PI first
Duration Time for Pt in Study: Screening: 1 visit Positive autoantibodies – See summary at right
Cross Recruitment OK?: Yes
Contact:
PI: Priya Prahalad, MD, PhD
Darrell Wilson, MD
Lead CRC:
Karen Barahona karenbb@stanford.edu

A 2:1 randomized clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D. Subjects receive either ATG or placebo in 2 infusions (overnight hospital stay), then come for F/U.

Information
Age:12-35 years
Main Eligibility Criteria:
-Stage 2 at Risk Subjects
-Must have at least two of the high-risk markers
-Abnormal glucose tolerance
Duration Time for Pt in Study: At least 24 Months
Cross Recruitment OK?: Contact PI
Contact:
PI: Priya Prahalad, MD, PhD
Darrell Wilson, MD
Lead CRCs:
Karen Barahona karenbb@stanford.edu
Trudy Esrey, RD, CDE; tesrey@stanford.edu

The Aim of this project is to make it easier for people with diabetes and their healthcare providers (HCPs) to access and utilize vetted, helpful exercise and physical activity (PA) guidance.

Information
Age:10 – 80 years
Main Eligibility Criteria:
-T1D and T2D
-English or Spanish Speaking
-Any Insurance
-On any Diabetes Technology
Duration Time for Pt in Study: 6 months
Cross Recruitment OK?: No
Contact:
PI: Dessi Zaharieva
Lead Project Manager: Lauren Figg lefigg@stanford.edu

Remote patient monitoring to promote access and sustained use of technology for youth from underserved backgrounds.

Information
Age:2 - 23 years
Main Eligibility Criteria:
-Seen at Stanford for diabetes care
-Willing to wear CGM/ share data
-CCS insurance
-Willing to attend pump class within 1 mo of start
Duration Time for Pt in Study: 1 year
Cross Recruitment OK?: Not while in first year of study. Can cross recruit after 12 months
Contact:
PI: Priya Prahalad, MD, PhD
4T Team: Stanford4Tstudy@stanford.edu 650-723-3383

This 4T sub-study uses physical activity trackers & telemedicine to implement exercise education modules to T1D pts. and families. Aims to reduce barriers associated with exercise by increasing knowledge around overall diabetes mgmt.

Information
Age:11-21 years
Main Eligibility Criteria:
-English or Spanish Speaking
-Enrolled in Main 4T Study
-Willing to wear physical activity tracker
Duration Time for Pt in Study: 1 year
Cross Recruitment OK?: Not while in first year of study. Can cross recruit after 12 months
Contact:
PI: Dessi Zaharieva, PhD
Lead CRCs:
Ana L Cortes: acortes@stanford.edu
Ilenia Balistreri illiee@stanford.edu

Remote patient monitoring for dose changes for newly diagnosed T1D kids, access to technology (Dexcom G6) close to diagnosis, additional exercise education for kids 11+.

Information
Age: 6 months -21 years
Main Eligibility Criteria:
-Seen at Stanford for diabetes care
-Willing to wear CGM/ share data
Duration Time for Pt in Study: 1 year
Cross Recruitment OK?: Not while in first year of study. Can cross recruit after 12 months
Contact:
PI: David Maahs, MD
4T Team: Stanford4Tstudy@stanford.edu 650-723-3383

A trial testing sequential therapy with Rituximab-pvvr (weekly infusions X4, no placebo), then weekly SQ abatacept or placebo injections at home X 20 months. Determining if Ritux followed by abatacept improves AUC CPeptide compared to Rituximab alone. Follow up Q 6 mos. X2 yrs.

Information
Age: 8-45 years
Main Eligibility Criteria:
-New Onset within 100 days of diagnosis
-English or Spanish Speaking
Duration Time for Pt in Study: 48 Months: 24 months of treatments, 24 months of follow up
Cross Recruitment OK?: Observational or Psychological/B ehavioral studies only
Contact:
PI: Priya Prahalad, MD, PhD and Darrell Wilson, MD
Lead CRCs:
Trudy Esrey tesrey@stanford.edu

Trial testing 2 JAK inhibitors, abrocitinib and ritlecitinib in new onset T1D participants. Randomized in a 1:1:1 allocation with placebo as 3rd arm. 12 months of active treatment (daily oral medication) with drug or placebo, then 12 months of F/U.

Information
Age: 12-35 years
Main Eligibility Criteria:
-New Onset T1D within 100 days of diagnosis
-English or Spanish Speaking
Duration Time for Pt in Study: 24 Months: 12 months of treatment; 12 months of follow up
Cross Recruitment OK?: No
Contact:
PI: Priya Prahalad, MD, PhD and Darrell Wilson, MD
Lead CRCs:
Trudy Esrey tesrey@stanford.edu

The Guided Transfer study investigates the effects of a guided transfer model to transition patients with chronic endocrinology conditions from pediatric to adult endocrinology clinic. You are eligible for this study if :

- T1D or Chronic Endo condition for > 1 yr & ready to transition to Stanford Adult Endocrinology Care
- English Speaking
- Followed in Stanford affiliated peds endo clinic (Dr. Lal’s patients excluded)
- ≥ 16 years

If you would like more information about this study, please contact Marci Morgan at madmorg@stanford.edu or 702-279-7870

Building the Evidence to Address Disparities in Type 1 Diabetes - We will utilize surveys and focus groups to identify barriers and promoters of diabetes technology use in youth with public insurance and T1D followed by an advisory board to develop an intervention.
-Duration: 1 year
-Main Eligibility Criteria: youth age <12, with public insurance, parent study (no youth participation)
To learn more about this study, please contact Ricardo Medina Penaranda at 661-616-8415 or ricarmp@stanford.edu.